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Bypass Graft in Stable Angina Patients
The Challenges and Potential of Observational Research
to Improve Care*John A. Spertus, MD, MPHI n this issue of the Journal, Zhang et al. andthe ASCERT (American College of CardiologyFoundation–The Society of Thoracic Surgeons
Collaboration on the Comparative Effectiveness of
Revascularization Strategies) investigators (1) have
extended their comparative effectiveness research
of percutaneous coronary intervention (PCI) and cor-
onary artery bypass graft (CABG) to examine costs.SEE PAGE 1This work leverages an important collaboration
between the American College of Cardiology and the
Society of Thoracic Surgeons to combine their proce-
dural PCI and CABG registries, which have previously
been used to describe the survival advantages of the 2
procedures in stable ischemic heart disease patients
with 2- or 3-vessel coronary disease (2). In this new
study, the data are linked to Medicare spending
from 2004 through 2008 to describe the differences
in costs of those ages >65 years and to estimate the
utilities (a coarse distillation of quality of life on the
basis of published data-supported, rather than pro-
spectively collected, estimates), lifetime costs, and
cost utility of these 2 treatment strategies. They*Editorials published in the Journal of the American College of Cardiology
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remains a reasonable value by commonly accepted
standards. These economic analyses are largely
congruent with, and driven by, the clinical results.
Zhang et al. (1) are to be commended for this sta-
tistical tour de force. Trying to estimate the beneﬁts of
1 treatment versus another using observational data is
always challenging, especially when substantial se-
lection biases related to the choice of therapy exist. In
this study, the lack of randomization ensures unmea-
sured confounding in their estimates, whichwas noted
in previous critiques of their original publication
(3,4). State-of-the-art techniques helped minimize
measured confounding, but the inability to adjust for
those unmeasured elements (e.g., lesion amenability
to PCI, patient preference) is an inherent problem
when using registries to compare treatment outcomes.
Even with propensity scoring and careful patient
selection to balance a myriad of measured patient
characteristics, factors left unmeasured can bias the
results. For example, in an important analysis of po-
tential selection biases when deciding to choose PCI
or CABG, McNulty et al. (5) noted that refusal by
surgeons to perform revascularization increased
mortality risk by more than 5-fold, yet these details
are not captured in the American College of Cardiol-
ogy or Society of Thoracic Surgeons registries. In fact,
the extreme divergence in propensity scores noted in
the original ASCERT publication (2) underscores how
truly different the patient populations undergoing
PCI and CABG are. As the investigators worked to
achieve balance in measured characteristics, they
excluded more than 90% of potential participants,
substantially limiting their ﬁndings’ generalizability.
These issues have led many to be skeptical of the
ASCERT clinical ﬁndings, even if the results are
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13correct. In this study, even more assumptions are
needed, not only for lifetime cost and survival
estimates, but particularly because the study did not
directly measure utilities. Nevertheless, these are
probably the best possible approximations that can be
obtained for the comparative cost effectiveness of
CABG versus PCI in routine practice, and Zhang et al.
(1) should be commended for their hard work.
Given the overall results that CABG is more
expensive but probably a reasonable value, what are
clinicians and policy makers to do with this infor-
mation? In practice, the choice of revascularization
strategy should ultimately be decided by the patient,
in consultation with their heart care team (6,7).
The choice should factor in many variables, but
most importantly there should be estimates of sur-
vival and health status (patient symptoms, function,
and quality of life) outcomes and the periprocedural
risks that patients are willing to accept to achieve
these outcomes. Not surprisingly, patients and pro-
viders are much more concerned about survival
and health status than the costs paid by Medicare.
Thus, this study likely does not have direct rele-
vance to clinical decision making, although the orig-
inal ASCERT publication does help, despite its
limitations, by providing likely survival advantages
with more patients alive at 30 days after PCI, no dif-
ference at 1 year, and more CABG patients surviving
at 4 years.
Critical gaps in knowledge remain, with little real-
world data comparing the health status advantages of
1 treatment strategy over the other (8), although 2
recent clinical trials document slightly better 1-year
symptom relief, function, and quality of life with
CABG (9,10). We urgently need more information to
better assist patients in making treatment decisions
and the American College of Cardiology and Society
of Thoracic Surgeons have a remarkable opportunity
to expand their PCI and CABG registries to include
patient-reported health status data, as they have with
their joint transcatheter valve therapy registry (11).
Were they to take the bold step of including health
status outcomes, then a much richer evidence base
would be available to help clinicians and patients
make difﬁcult treatment decisions.
Another gap in knowledge relates to the lack of data
enabling personalized outcomes estimates. There is a
well-recognized heterogeneity of treatment beneﬁt formost procedures, with some patients deriving great
beneﬁt, others modest beneﬁt, and others being
harmed by treatment (12). Zhang et al. (1) examined
cost-effectiveness in several distinct subgroups (by
age, diabetes status, number of diseased vessels, and
presence of heart failure), but what if patients have
multiple conditions? Currently, no method exists to
extrapolate these data to the complex patients typi-
cally seen in routine clinical practice.What is needed is
to more formally model outcomes and to test the
interaction and main effects of treatment alternatives
across the range of risks for survival and health status
outcomes. A recent example from the TRITON-TIMI 38
(Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition With Prasu-
grel—Thrombolysis in Myocardial Infarction 38) study
shows how simple the outcomes of alternative treat-
ments can be compared, even when multiple risk fac-
tors need to be considered (13). Yet, building these
models requires that registries collect those outcomes
most important to patients, including health status at
the time of treatment and over time, so that the
research enterprise can build appropriate tools to help
support clinical care. Ideally, such assessments would
include those patients who do not undergo revascu-
larization at all but, to date, only the Canadian
APPROACH (Alberta Provincial Project for Outcome
Assessment in Coronary Heart Disease) registry has
extended data collection to include medically treated
patients’ health status outcomes (14).
From my perspective, the ASCERT registry takes an
important ﬁrst step in assessing the comparative
effectiveness of alternative revascularization techni-
ques, but it also highlights important gaps in existing
data and the challenge of assessing therapeutic
effectiveness from observational data. The use of
registry data to support shared medical decision
making is tantalizingly close, but requires a strong
commitment by clinicians and researchers to collect
data and build tools that patients can use to help
make decisions that are aligned with their personal
goals and values.
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